E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Post-herpetic neuralgia symptom relief. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the analgesic efficacy of Sativex® compared with placebo, when added to existing treatment regimens, in relieving post-herpetic neuralgia (PHN). |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effect of Sativex® compared with placebo on:· Secondary measures of pain relief Brief Pain Inventory (BPI) Subject Global Impression of Change Sleep quality
To assess the safety and tolerability of Sativex® |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects meeting the following criteria will be considered eligible for this study:· -Subjects aged 18 years or above.· -Diagnosed with post-herpetic neuralgia, of at least three months duration since rash healing, in whom pain is not wholly relieved with their current therapy. · -Subject has at least moderate pain (due to PHN), which is defined by: NRS pain scores on all of baseline days B2 to B7 have been recorded, via the IVRS, by the subject and sum to at least 24. -Subject fulfils at least one of the two criteria below. Subject must be either:- Currently established on a regular dose of analgesic therapy for their PHN. Previously tried and failed or could not tolerate analgesic therapy for their PHN. -Stable medication regimen for at least 2 weeks prior to study entry, for all medications that may have an affect on neuropathic pain, except paracetamol/ acetaminophen. -Subject is willing to stop taking their own paracetamol/acetaminophen or paracetamol/acetaminophen containing medications and start using study medication paracetamol/acetaminophen as required (prn) for the duration of the study. -Subject is willing to maintain a stable dose of medications that may have an effect on neuropathic pain, other than study medication and paracetamol/acetaminophen, for the duration of the study. |
|
E.4 | Principal exclusion criteria |
The subject may not enter the study if ANY of the following apply:· -Subjects, whose identified pain is likely to be of a nociceptive, musculoskeletal, central neuropathic or psychogenic origin. -Other pain, which is not of a peripheral neuropathic origin thought by the investigator to be of a nature or severity to interfere with the subject’s assessment of PHN. -Currently receiving a prohibited medication and unwilling to stop or comply for the duration of the study. -Currently using or has used recreational cannabis, medicinal cannabis (including Sativex®), or synthetic cannabinoid based medications within 3 months prior to study entry and unwilling to abstain for the duration for the study. -Any known or suspected history of:- or family history of schizophrenia, other psychotic illness- alcohol or substance abuse- epilepsy or recurrent seizures- hypersensitivity to cannabinoids· -Significant cardiac, renal or hepatic impairment. -If female, is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter. -Travel outside the country of residence planned during the study. -Subjects who have received an Investigational Medicinal Product within the 12 weeks before the screening visit. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the mean pain (due to PHN) numeric rating scale (NRS) score at the end of treatment (usually week 14). The variable for analysis will be the change in mean NRS from baseline to the end of the treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |